First of all check the meaning of "age-adjusted" and read the link again (with this knowledge).
Do you realize that it means that JELIS was over (and not underreported)? Maybe the "real" rate was lower ...
Yes, the statin is more intensive than in JELIS But it is irrelevent, since if JELIS could give any guidance (as I think) it gives about R-IT active / V arm and not about the placebo. Crestor was approved in 2004, R-IT design was finalized in 2011. What is the new information (was available after R-IT design) that could affect the placebo estimation? Please notre: new means the trend / relation / etc wasn't known before final R-IT design and data about recent years (was available for previous years) won't be counted as new. e.g. CVD rate between 2011-2014 isn't a new information, since the trend was the same between 2000-2010.